Tesaro Garners $101,000,000 Series B Financing Round

  • Feed Type
  • Date
    6/21/2011
  • Company Name
    Tesaro
  • Mailing Address
    135 Clarendon St. Boston, MA 02116
  • Company Description
    TESARO is a privately held oncology-focused biopharmaceutical company whose passionate associates are dedicated to improving the lives of cancer patients by developing and providing safer and more effective therapeutics and supportive care products.
  • Website
    http://www.tesarobio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $101,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    TESARO plans to develop one or more compounds for oncology indications, including the treatment of patients with non-small cell lung cancer (NSCLC) whose tumors express an ALK fusion protein; recent clinical proof-of-concept has been demonstrated for ALK inhibition in this patient population. The Series B financing will fund further development of these programs and expansion of the pipeline.
  • M&A Terms
  • Venture Investor
    Kleiner Perkins Caufield & Byers
  • Venture Investor
    InterWest Partners
  • Venture Investor
    New Enterprise Associates
  • Venture Investor
    New Enterprise Associates
  • Venture Investor
    Pappas Ventures
  • Venture Investor
    Deerfield Capital
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.